Edgar Filing: ANTIGENICS INC /DE/ - Form 4

ANTIGEN	ICS INC /DE/										
Form 4											
January 05,	2010										
FORM 4 UNITED STATES SECURITIES AND EXCHANCE COMMISSION									PPROVAL		
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549									3235-0287		
Check t				U				Expires:	January 31,		
if no longer subject to STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF									2005		
subject to Section 16. SECURITIES									Estimated average burden hours per		
Form 4	Form 4 or								. 0.5		
Form 5	Filed put	rsuant to S	Section	16(a) of tl	ne Securit	ies Excha	nge Act of 1934,				
obligati may coi				•	•	• •	of 1935 or Section	on			
See Inst		30(h)	of the I	nvestmen	t Compan	y Act of 1	940				
1(b).											
(Print or Type	Responses)										
	Address of Reporting	Person [*]	2. Issuer Name and Ticker or Trading				5. Relationship of Reporting Person(s) to				
DECHAEN	NE TOM		Symbol				Issuer				
		ANTIC	GENICS I	NC /DE/	[AGEN]						
(Last) (First) (Middle)			3 Date	of Earliest T	ransaction		(Check all applicable)				
(Last) (First) (Wildle)			(Month/Day/Year)				X Director	109	% Owner		
C/O ANTIGENICS INC., 162			01/01/2010			Officer (giv	e title Oth	ner (specify			
FIFTH AV						below) below)					
(Street)			4. If Amendment Date Original				6. Individual or Joint/Group Filing(Check				
(Succi)			4. If Amendment, Date Original Filed(Month/Day/Year)			Applicable Line)					
Thed(Month/Day/Tear			u)		11 /	y One Reporting Person					
NEW YORK, NY 10010						Form filed by More than One Reporting					
							Person				
(City)	(State)	(Zip)	Tal	ole I - Non-	Derivative	Securities A	cquired, Disposed	of, or Beneficia	lly Owned		
1.Title of	2. Transaction Date	2A. Deem	ed	3.	4. Securiti	es	5. Amount of	6. Ownership	7. Nature of		
Security	(Month/Day/Year)	Execution	Date, if		nAcquired			Form: Direct	Indirect		
(Instr. 3)		any		Code	Disposed		•	(D) or Indirect			
		(Month/Da	ay/Year)	(Instr. 8)	(Instr. 3, 4	and 5)		(I) (Instr. 4)	Ownership (Instr. 4)		
						(•)	Reported	(insu: i)	(Instr. 1)		
						(A) or	Transaction(s)				
				Code V	Amount	(D) Price	(Instr. 3 and 4)				
Reminder: Re	port on a separate line	e for each cl	ass of sec	urities bene	-	-	-				
							spond to the colle tained in this form		SEC 1474 (9-02)		
							ond unless the fo		(9-02)		
							ntly valid OMB co				
					numb	-					

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transaction	orDerivative	Expiration Date	Underlying Securities
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

Edgar Filing: ANTIGENICS INC /DE/ - Form 4

(Instr. 3)	. 3) Price of Derivative Security		(Month/Day/Year)	(Instr.	í	Acquired (A Disposed of (Instr. 3, 4, a 5)	(D)				
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Deferred Shares (1)	<u>(1)</u>	01/01/2010		А		2,530.81		<u>(1)</u>	(1)	Common Stock	2,530.81

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
DECHAENE TOM C/O ANTIGENICS INC. 162 FIFTH AVENUE, SUITE 900 NEW YORK, NY 10010	Х						
Signatures							
Christine M. Klaskin, by Power of Attorney	01/05/2010						
**Signature of Reporting Person	Date						

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Acquired under the Antigenics Directors' Deferred Compensation Plan, as amended. Deferred shares represent an equal amount of shares(1) of the Company's common stock to be distributed with the terms of the Plan, typically once the director ceases to serve as a director of the Company.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.